MetaCap

MBX Biosciences (MBX) vs Pharvaris N.V. (PHVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MBX Biosciences (MBX) has outperformed Pharvaris N.V. (PHVS) over the past year, gaining 83.0% versus a gain of 26.0%. MBX Biosciences is the larger company by market cap ($2.46 billion vs $2.21 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBX+82.98%PHVS+25.98%
+169%+78%-13%
Nov 21, 20251 yearNov 20, 2026
MBX+109.51%PHVS+49.52%
+203%+58%-88%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBX versus PHVS key metrics
MetricMBXPHVS
Share price$49.55$31.28
Market cap$2.46B$2.21B
1-day change-7.23%-1.20%
YTD return+57.10%+12.72%
1-year return+82.98%+25.98%
5-year return—+131.28%
EPS (TTM)$-3.03$-3.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-87.00M$-25.99M
52-week high$72.64$43.25
52-week low$26.14$23.15
Distance from 52-week high-31.79%-27.68%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+91.91%+86.29%
Average volume532.80K756.20K
Shares outstanding49.66M70.79M
Employees63168
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MBX has outperformed PHVS by 57.0 percentage points over the past year.

About MBX Biosciences

MBX stock →

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

About Pharvaris N.V.

PHVS stock →

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.

Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees

MBX vs PHVS FAQ

Which is bigger, MBX Biosciences or Pharvaris N.V.?

MBX Biosciences (MBX) is larger, with a market capitalization of $2.46B compared with $2.21B for Pharvaris N.V. (PHVS).

Which stock has performed better over the past year, MBX or PHVS?

MBX returned +82.98% over the past 12 months, compared with +25.98% for PHVS (price return, excluding dividends). Past performance does not predict future results.

Are MBX Biosciences and Pharvaris N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons